AR065718A1 - Compuestos heterociclicos nitrogenados,utiles en el diagnostico y tratamiento de trastornos hiperproliferativos. - Google Patents

Compuestos heterociclicos nitrogenados,utiles en el diagnostico y tratamiento de trastornos hiperproliferativos.

Info

Publication number
AR065718A1
AR065718A1 ARP080101030A ARP080101030A AR065718A1 AR 065718 A1 AR065718 A1 AR 065718A1 AR P080101030 A ARP080101030 A AR P080101030A AR P080101030 A ARP080101030 A AR P080101030A AR 065718 A1 AR065718 A1 AR 065718A1
Authority
AR
Argentina
Prior art keywords
het
aryl
substituted
alkyl
unsubstituted
Prior art date
Application number
ARP080101030A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39472520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065718(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR065718A1 publication Critical patent/AR065718A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Abstract

Reivindicacion 1: Un compuesto de la formula (1) y las sales farmacéuticamente aceptables del mismo, en donde: R1 es fenilo que puede estar insustituido o sustituido; R2 es het, siendo N cuando menos un heteroátomo del anillo, y el cual puede estarinsustituido o sustituido; L es alquilo inferior, (CH2)1-2-A, A-(CH2)1-2, o CH2-A-CH2, y A es O, S, NH, o N-aIquilo, en donde alquilo inferior puede estar insustituido o sustituido con alquilo inferior, o uno o más átomos de fluor; X es N o CH, ycuando menos un X es N; Y es un enlace, CH2, C(O), o SO2; R3 es arilo o het, el cual está sustituido, Z es H, alquilo inferior, alcoxilo inferior, oxo, C(O)OR6, o -CN; en donde alquilo inferior y alcoxilo inferior pueden estar insustituidos osustituidos con uno o más de halogeno, -OH, -CN, -NH2, u oxo, y dos Z conectados al mismo átomo pueden formar un anillo de cicloalquilo, y m es de 0 a 3, las sustituciones de fenilo, arilo o het de R1, R2, o R3 pueden ser uno o más de alquilo,cicloalquilo, alcoxilo, cicloalcoxilo, halogeno, -CN, oxo, arilo, carbalcoxilo, OCF3, CF3, OH, -C(O)N(R6)2, C(O)R6, -C(O)OR6, -N(R6)2, -NHC(O)R6, -SO2(R6), -SO2N(R6)2, CH2OC(O)N(R6)2, -CH2N(R6)2, -NHC(O)OR6, NHC(O)N(R6)2, -CH2NHC(O)R6,CH2NHC(O)N(R6)2, CH2NHSO2(R6), CHNHC(O)OR6, -OC(O)R6, NHC(O)R6, O-arilo, het, u O-het, en donde alquilo, het, cicloalquilo, cicloalcoxilo, N(R6)2, arilo, carbalcoxilo, y alcoxilo pueden estar insustituidos o sustituidos con uno o más de halogeno, -OCH3, -OCF3, -OH, -NH2, alquilo, OR6, oxo, N(H)0-2-R6, -CN, -C(O)N(R6)2, C(O)R6, C(O)OR6, -N(R6)2, NHC(O)R6, -SO2(R6), -SO2N(R6)2, OSO2R6, -CH2N(R6)2, -CH2NHC(O)R6, -OC(O)R6, arilo, NHC(O)-(R6), O-arilo, het, O-het, o cicloalquilo; R6 es H, alquilo,alquenilo, arilo, het, o dos R6 sobre un átomo pueden formar cicloalquilo, arilo, o het; y alquilo, alquenilo, arilo, het, cicloalquilo, o het pueden estar insustituidos o sustituidos por OH, oxo, alcoxilo, NR6, N-alquilo, acilo, arilo o un grupohet; het es un anillo heterocíclico monocíclico de 5 a 7 miembros, el cual puede ser aromático o no aromático, que contiene de 1 a 4 heteroátomos del anillo seleccionados a partir de N, O, y S; o un sistema de anillos fusionados de 8 a 12 miembrosque incluye cuando menos un anillo heterocíclico de 5 a 7 miembros, el cual puede ser aromático o no aromático, que contiene 1, 2, o 3 heteroátomos de anillo seleccionados a partir de N, O y S, cuyo het está insustituido o sustituido; arilo es unradical aromático que tiene de 6 a 14 átomos de carbono del anillo, y ningun heteroátomo del anillo, en donde este grupo arilo puede ser monocíclico o bicíclico o tricíclico fusionado, que puede estar insustituido o sustituido por uno o mássustituyentes; y n es 0, 1, 2, o 3.
ARP080101030A 2007-03-15 2008-03-13 Compuestos heterociclicos nitrogenados,utiles en el diagnostico y tratamiento de trastornos hiperproliferativos. AR065718A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89499107P 2007-03-15 2007-03-15

Publications (1)

Publication Number Publication Date
AR065718A1 true AR065718A1 (es) 2009-06-24

Family

ID=39472520

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101030A AR065718A1 (es) 2007-03-15 2008-03-13 Compuestos heterociclicos nitrogenados,utiles en el diagnostico y tratamiento de trastornos hiperproliferativos.

Country Status (33)

Country Link
US (1) US8536168B2 (es)
EP (1) EP2137162B1 (es)
JP (1) JP5550352B2 (es)
KR (1) KR101473504B1 (es)
CN (1) CN101657430B (es)
AR (1) AR065718A1 (es)
AU (1) AU2008225766B2 (es)
BR (1) BRPI0809193A2 (es)
CA (1) CA2681162C (es)
CL (1) CL2008000754A1 (es)
CO (1) CO6220967A2 (es)
CR (1) CR11016A (es)
CU (1) CU23769B7 (es)
DK (1) DK2137162T3 (es)
DO (1) DOP2009000217A (es)
EA (1) EA016564B1 (es)
EC (1) ECSP099636A (es)
GE (1) GEP20125487B (es)
GT (1) GT200900244A (es)
IL (1) IL200654A (es)
MA (1) MA31258B1 (es)
MX (1) MX2009009873A (es)
MY (1) MY156814A (es)
NI (1) NI200900168A (es)
NZ (1) NZ579402A (es)
PE (1) PE20090188A1 (es)
SG (1) SG182205A1 (es)
SM (1) SMP200900082B (es)
TN (1) TN2009000373A1 (es)
TW (1) TWI406857B (es)
UA (1) UA100684C2 (es)
WO (1) WO2008110611A1 (es)
ZA (1) ZA200905949B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
UA100684C2 (uk) 2007-03-15 2013-01-25 Новартіс Аг Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
CN101801954B (zh) 2007-09-20 2013-10-09 Irm责任有限公司 作为gpr119活性调节剂的化合物和组合物
WO2009086451A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
PE20091556A1 (es) * 2008-02-26 2009-11-03 Takeda Pharmaceutical Derivado heterociclico fusionado y su uso
WO2009134574A2 (en) * 2008-04-29 2009-11-05 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CN102170873B (zh) * 2008-10-01 2014-07-30 诺华股份有限公司 用于治疗与hedgehog通路有关的病症的smoothened拮抗
NZ591945A (en) * 2008-11-03 2012-10-26 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
US8445493B2 (en) 2008-11-17 2013-05-21 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
DK2358698T3 (da) * 2008-11-17 2012-10-08 Lilly Co Eli Tetrasubstitueret pyridazin som hedgehog-pathway antagonister
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
US20110039850A1 (en) * 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
NZ598588A (en) * 2009-08-25 2014-05-30 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
CA2781210A1 (en) * 2009-11-18 2011-05-26 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US9006450B2 (en) 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
CA2824197C (en) 2011-01-10 2020-02-25 Michael Martin Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
RU2014111823A (ru) 2011-08-29 2015-10-10 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
EP2785690B1 (en) * 2011-12-02 2016-07-13 Boehringer Ingelheim International GmbH Piperidine derivatives, pharmaceutical compositions and uses thereof
EA037918B1 (ru) 2011-12-21 2021-06-07 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201605291WA (en) 2012-08-28 2016-08-30 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
PT2914296T (pt) 2012-11-01 2018-10-30 Infinity Pharmaceuticals Inc Tratamento de cancros utilizando moduladores de isoformas de pi3-quinase
CA2893133A1 (en) 2012-11-29 2014-06-05 Strasspharma Llc Methods of modulating follicle stimulating hormone activity
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
BR112015025052A2 (pt) 2013-04-03 2021-07-06 Janssen Sciences Ireland Uc derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
PL2997019T3 (pl) 2013-05-17 2019-03-29 Janssen Sciences Ireland Uc Pochodne sulfamoilotiofenamidu i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
KR20160013204A (ko) 2013-05-30 2016-02-03 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
AP2015008968A0 (en) 2013-07-25 2015-12-31 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives andthe use thereof as medicaments for the treatment of hepatitis b
BR112016007467B1 (pt) 2013-10-04 2022-09-20 Infinity Pharmaceuticals, Inc Compostos heterocíclicos e usos dos mesmos
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3060547B1 (en) 2013-10-23 2017-10-11 Janssen Sciences Ireland UC Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2015107493A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
US9815813B2 (en) 2014-01-17 2017-11-14 Novartis Ag 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
ES2792848T3 (es) 2014-02-05 2020-11-12 Novira Therapeutics Inc Politerapia para el tratamiento de infecciones por VHB
EA035848B1 (ru) 2014-02-06 2020-08-20 Янссен Сайенсиз Айрлэнд Юси Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
CN113620958A (zh) 2014-03-19 2021-11-09 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
JP6796638B2 (ja) 2015-06-04 2020-12-09 ペレファーム, インク.Pellepharm, Inc. ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
CN107922388B (zh) 2015-06-19 2020-12-29 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
ES2741746T3 (es) 2015-06-19 2020-02-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017059059A1 (en) 2015-09-29 2017-04-06 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
US10195283B2 (en) * 2016-03-18 2019-02-05 R.P. Scherer Technologies, Llc Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate
SG11201808949SA (en) 2016-04-15 2018-11-29 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3468972T (pt) 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
KR20200095467A (ko) 2017-10-27 2020-08-10 베링거 인겔하임 인터내셔날 게엠베하 피리딘 카보닐 유도체 및 trpc6 억제제로서 이의 치료학적 용도
DE102018105524A1 (de) * 2018-03-09 2019-09-12 Universität Duisburg-Essen Verwendung von Modulatoren der Sphingosin-1-phosphat-Signaltransduktion
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
WO2020007807A1 (en) * 2018-07-02 2020-01-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof
CN108997224B (zh) * 2018-08-28 2023-04-28 韶远科技（上海)有限公司 一种2-氯-5-氰基含氮六元杂环化合物的制备方法
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
TW202045499A (zh) 2019-02-22 2020-12-16 愛爾蘭商健生科學愛爾蘭無限公司 用於治療ｈｂｖ感染或ｈｂｖ誘發疾病之醯胺衍生物
CA3132554A1 (en) 2019-05-06 2020-11-12 Bart Rudolf Romanie Kesteleyn Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
CN110845426A (zh) * 2019-11-29 2020-02-28 都创(上海)医药科技有限公司 一种2-氯-5-氰基嘧啶化合物制备方法
KR102394110B1 (ko) * 2020-01-22 2022-05-04 가톨릭대학교 산학협력단 신규 화합물 및 이의 용도
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
CN116199625A (zh) * 2023-01-19 2023-06-02 上海昱菘医药科技有限公司 一种烟酸酯类化合物的制备方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
US3668207A (en) * 1970-01-22 1972-06-06 Ciba Geigy Corp 2-amino-4-aryl-quinolines
DE2643753A1 (de) * 1976-09-29 1978-04-06 Thomae Gmbh Dr K Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine
FR2421900A1 (fr) * 1977-03-17 1979-11-02 Sauba Lab Piperazino-3-indoles, leur procede de preparation et leurs applications therapeutiques
FI70411C (fi) 1980-12-29 1986-09-19 Pfizer Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat
MA20387A1 (fr) * 1984-03-26 1985-10-01 Janssen Pharmaceutica Nv Pyridazinamines utiles comme agents anti-viraux et procede pour leur preparation
EP0157037A3 (en) 1984-03-29 1986-11-05 Bowmar Instrument Corporation Long-stroke push-button switch
US4569934A (en) 1984-10-09 1986-02-11 American Cyanamid Company Imidazo[1,2-b]pyridazines
CA1307786C (en) 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
US4760064A (en) * 1984-12-18 1988-07-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
JP2544939B2 (ja) 1987-09-01 1996-10-16 大塚製薬株式会社 ベンゾヘテロ環誘導体
JPH02193992A (ja) * 1989-01-23 1990-07-31 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
AU705229B2 (en) 1994-08-09 1999-05-20 Eisai R&D Management Co., Ltd. Fused pyridazine compound
JP3919835B2 (ja) * 1994-08-09 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリダジン系化合物
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
TR200003004T2 (tr) 1998-04-20 2001-02-21 Basf Aktiengesellschaft Kalpain önleyicileri olarak heterosiklik ikame edilmiş amidler
KR20010053254A (ko) 1998-06-30 2001-06-25 둘락 노먼 씨. 무스카린성 길항제
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
EP1146871A4 (en) 1999-01-28 2002-04-17 Bristol Myers Squibb Co HETEROCYCLIC ANTIDEPRESSANT COMPOUNDS
JP2000281660A (ja) 1999-03-29 2000-10-10 Sumitomo Pharmaceut Co Ltd キナゾリン誘導体
AU766081B2 (en) * 1999-03-30 2003-10-09 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
IL145741A0 (en) 1999-05-04 2002-07-25 Schering Corp Piperazine derivatives useful as ccrs antagonists
ES2165274B1 (es) 1999-06-04 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
JP2003501395A (ja) 1999-06-08 2003-01-14 ローランティス・リミテッド 治療的使用
FR2803593B1 (fr) * 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2407573C (en) 2000-04-27 2011-09-13 Yamanouchi Pharmaceutical Co. Ltd. Imidazopyridine derivatives
DE10043659A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
ES2172436B1 (es) * 2000-10-31 2004-01-16 Almirall Prodesfarma Sa Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
EP1353674A1 (en) 2000-12-29 2003-10-22 Alteon, Inc. Method for treating glaucoma ivb
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
WO2002080952A2 (en) 2001-04-09 2002-10-17 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
JP4929547B2 (ja) 2001-09-03 2012-05-09 コニカミノルタホールディングス株式会社 アゾメチン化合物、アゾメチン化合物と金属イオン含有化合物との混合物、感熱転写記録材料、カラートナー
ATE369854T1 (de) 2001-10-19 2007-09-15 Ortho Mcneil Pharm Inc 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs
PT1956004E (pt) * 2002-03-27 2012-08-31 Glaxo Group Ltd Derivados de quinolina e sua utilização como ligandos 5-ht6
US20060290712A1 (en) 2002-10-16 2006-12-28 Electronics And Telecommunications Research Institute Method and system for transforming adaptively visual contents according to user's symptom characteristics of low vision impairment and user's presentation preferences
PL378295A1 (pl) 2003-02-24 2006-03-20 Arena Pharmaceuticals, Inc. Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu
EP2316826A1 (en) * 2003-07-30 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutics agents
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
WO2005020897A2 (en) 2003-08-22 2005-03-10 Dendreon Corporation Compositions and methods for the treatment of disease associated with trp-p8 expression
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
JP5143558B2 (ja) * 2004-09-02 2013-02-13 ジェネンテック，インコーポレイティド ヘッジホッグシグナル伝達のピリジルインヒビター
GB0422263D0 (en) * 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
DE102005023943A1 (de) 2005-05-20 2006-11-23 Grünenthal GmbH Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln
NZ564222A (en) 2005-06-14 2011-10-28 Taigen Biotechnology Co Ltd Pyrimidine compounds
US8364148B2 (en) 2005-07-07 2013-01-29 Qualcomm Incorporated Methods and devices for interworking of wireless wide area networks and wireless local area networks or wireless personal area networks
WO2007059157A1 (en) 2005-11-14 2007-05-24 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
NZ568666A (en) * 2005-11-30 2011-09-30 Vertex Pharma [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole derivative as inhibitors of c-Met
GB0602335D0 (en) * 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
AR059898A1 (es) * 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
WO2007109238A1 (en) * 2006-03-21 2007-09-27 Schering Corporation Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity
WO2007127475A2 (en) 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
EP1849781A1 (en) * 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
AU2007243280A1 (en) 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
EP2015751A2 (en) 2006-04-28 2009-01-21 Northwestern University Salts of pyridazine compounds
KR20090043512A (ko) 2006-07-14 2009-05-06 쉐링 코포레이션 Ｃｘｃｒ3 길항제 활성을 갖는 헤테로사이클릭 치환된 피페라진 화합물
GB0623258D0 (en) * 2006-11-22 2007-01-03 Remynd Nv Thiadiazole derivatives for the treatment of neuro-degenerative diseases
BRPI0720789A2 (pt) 2006-12-14 2014-03-11 Syngenta Participations Ag Herbicidas
JP2010513520A (ja) 2006-12-22 2010-04-30 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有する複素環式化合物
TW200900391A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CA2680583A1 (en) 2007-03-15 2008-09-25 Schering Corporation Pyridazinone derivatives useful as glucan synthase inhibitors
EP2121579B1 (en) 2007-03-15 2011-04-20 F. Hoffmann-La Roche AG Malonamides as orexin antagonists
UA100684C2 (uk) 2007-03-15 2013-01-25 Новартіс Аг Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
WO2009035568A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
GB0808888D0 (en) * 2008-05-15 2008-06-25 Syngenta Participations Ag Insecticidal compounds
AU2009266001B2 (en) * 2008-07-03 2014-03-27 Janssen Pharmaceutica Nv Substituted 6- (1-piperazinyl) -pyridazines as 5-HT6 receptor antagonists
WO2010006096A1 (en) * 2008-07-11 2010-01-14 Smithkline Beecham Corporation Processes for the preparation of anti-viral compounds and compositions containing them
US20110301162A1 (en) * 2008-08-04 2011-12-08 Amgen Inc. Aurora kinase modulators and methods of use
NZ591945A (en) * 2008-11-03 2012-10-26 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
FR2939134A1 (fr) 2008-12-01 2010-06-04 Sanofi Aventis Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
TWI520989B (zh) * 2015-03-02 2016-02-11 國立交通大學 製備高分子球的方法

Also Published As

Publication number Publication date
TN2009000373A1 (en) 2010-12-31
PE20090188A1 (es) 2009-03-20
UA100684C2 (uk) 2013-01-25
TW200848414A (en) 2008-12-16
JP2010521438A (ja) 2010-06-24
BRPI0809193A2 (pt) 2014-09-23
WO2008110611A1 (en) 2008-09-18
MA31258B1 (fr) 2010-03-01
EP2137162B1 (en) 2018-08-01
GEP20125487B (en) 2012-04-25
SG182205A1 (en) 2012-07-30
ECSP099636A (es) 2009-10-30
US8536168B2 (en) 2013-09-17
AU2008225766B2 (en) 2012-06-07
KR20090121386A (ko) 2009-11-25
SMP200900082B (it) 2010-09-10
CL2008000754A1 (es) 2008-10-24
CA2681162C (en) 2015-11-24
JP5550352B2 (ja) 2014-07-16
ZA200905949B (en) 2010-10-27
EA016564B1 (ru) 2012-05-30
CU23769B7 (es) 2012-02-15
TWI406857B (zh) 2013-09-01
EP2137162A1 (en) 2009-12-30
CR11016A (es) 2009-10-06
NZ579402A (en) 2012-03-30
GT200900244A (es) 2010-03-15
CN101657430B (zh) 2013-05-01
DK2137162T3 (en) 2018-11-26
US20100069368A1 (en) 2010-03-18
MX2009009873A (es) 2009-09-24
EA200901170A1 (ru) 2010-04-30
MY156814A (en) 2016-03-31
CO6220967A2 (es) 2010-11-19
CN101657430A (zh) 2010-02-24
AU2008225766A1 (en) 2008-09-18
SMAP200900082A (it) 2009-11-06
CU20090159A7 (es) 2011-04-26
KR101473504B1 (ko) 2014-12-16
CA2681162A1 (en) 2008-09-18
IL200654A0 (en) 2010-05-17
DOP2009000217A (es) 2009-10-31
IL200654A (en) 2015-03-31
NI200900168A (es) 2010-09-09

Similar Documents

Publication Publication Date Title
AR065718A1 (es) Compuestos heterociclicos nitrogenados,utiles en el diagnostico y tratamiento de trastornos hiperproliferativos.
AR077147A1 (es) Compuestos biciclicos y triciclicos como inhibidores de kat ii
AR058984A1 (es) Derivados de ciclohexil piperazinil metanona
AR069849A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
AR050953A1 (es) Compuestos de sulfonamida inhibidores de los receptores de cck1/cck2 duales
AR065322A1 (es) 2-aminooxazolinas comoligandos de taar1
AR060807A1 (es) Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek
ES2655391T3 (es) Inhibidores isoindolinona de fosfatidilinositol 3-quinasa
CO6140056A2 (es) Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa
AR048789A1 (es) Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
PE20080841A1 (es) Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion
AR067413A1 (es) Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
AR073406A1 (es) Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer.
AR084457A1 (es) Derivados de biciclo[3,2,1]octilamida
AR081075A1 (es) Derivados de imidazo[1,2-c]pirimidina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes e inflamatorias.
AR076098A1 (es) Derivados de benzofurano
CO6160296A2 (es) Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
AR040626A1 (es) Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)
AR070274A1 (es) Derivados arilamida diazepinopirimidona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios.
PE20120900A1 (es) Compuestos heterociclicos de fenoximetilo
AR049954A1 (es) Derivados de azepina sustituidos como moduladores de los receptores de la serotonina
AR066421A1 (es) Compuestos derivados de piridona
AR046603A1 (es) Alcanaminas dihidrobenzofuranilo y metodos para su uso como farmacos en el snc
AR070635A1 (es) DERIVADOS DE PIRIDOPIRAZINONA QUE ESTIMULAN LA SECRECIoN DE INSULINA, MÉTODOS PARA OBTENERLOS, SU USO EN EL TRATAMIENTO DE LA DIABETES Y COMPOSICIONES FARMACEUTICAS.

Legal Events

Date Code Title Description
FB Suspension of granting procedure